Basic Concepts in Insulin Resistance and Diabetes Treatment

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-72475-1_3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018cited by this paper
• Do we know the true mechanism of action of the DPP‐4 inhibitors?

  2018cited by this paper
• Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.

  2017cited by this paper
• The mechanisms of action of metformin

  2017cited by this paper
• Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action

  2017cited by this paper
• Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials

  2017cited by this paper
• Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

  2017cited by this paper
• Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

  2017cited by this paper
• Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

  2017cited by this paper
• Adolescent Obesity and Insulin Resistance: Roles of Ectopic Fat Accumulation and Adipose Inflammation.

  2017cited by this paper
• Weight and Metabolic Outcomes 12 Years after Gastric Bypass

  2017cited by this paper
• Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

  2017cited by this paper
• Role of immune cells in obesity induced low grade inflammation and insulin resistance.

  2017cited by this paper
• Pioglitazone use and risk of bladder cancer: population based cohort study

  2016cited by this paper
• Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies

  2016cited by this paper
• Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Medication‐induced diabetes mellitus

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Human genetic lessons.

  2016cited by this paper
• Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.

  2016cited by this paper
• Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries

  2016cited by this paper
• Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.

  2016cited by this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cited by this paper
• Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

  2016cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

  2015cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

  2015cited by this paper
• Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

  2015cited by this paper
• Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

  2015cited by this paper
• Type 2 diabetes mellitus

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015cited by this paper
• Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study

  2014cited by this paper
• Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment

  2014cited by this paper
• Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

  2014cited by this paper
• Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

  2014cited by this paper
• Increased expression of glucagon‐like peptide‐1 receptors in psoriasis plaques

  2013cited by this paper
• The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus

  2013cited by this paper
• Dichotomous roles of leptin and adiponectin as enforcers against lipotoxicity during feast and famine

  2013cited by this paper
• Genetics in endocrinology: genetic forms of severe insulin resistance: what endocrinologists should know.

  2013cited by this paper
• Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

  2013cited by this paper
• The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease

  2012cited by this paper
• Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

  2012cited by this paper
• Adaptive immunity in obesity and insulin resistance

  2012cited by this paper
• Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.

  2012cited by this paper
• Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

  2012cited by this paper
• Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus

  2012cited by this paper
• Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

  2011cited by this paper
• Genetic syndromes of severe insulin resistance.

  2011cited by this paper
• Skeletal Muscle Triglycerides, Diacylglycerols, and Ceramides in Insulin Resistance

  2011cited by this paper
• Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology

  2011cited by this paper
• Bariatric Surgery for Type 2 Diabetes Reversal: The Risks

  2011cited by this paper
• The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes

  2010cited by this paper
• The Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity

  2009cited by this paper
• Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses

  2009cited by this paper
• Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus

  2009cited by this paper
• Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects.

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

  2008cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  2006cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Dose-response effect of elevated plasma free fatty acid on insulin signaling.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes.

  2004cited by this paper
• A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.

  2003cited by this paper
• Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis.

  2001cited by this paper
• Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications

  1995cited by this paper
• Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man

  1994cited by this paper

• Effect of Calorie Restriction and Exercise on Type 2 Diabetes

  2021cites this paper
• Serum selenoprotein P in lean and obese Egyptian individuals and its relation to insulin resistance

  2021cites this paper
• Insulin Signal Transduction Perturbations in Insulin Resistance

  2021cites this paper
• Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation

  2019cites this paper
• Effects of Hypoglycemic Anti-Deafness Prescription on Insulin Resistance in Patients with Diabetes Mellitus and Deafness

  2019cites this paper
• View Insulin Resistance from an Interaction Between Pancreatic Islets and Peripheral Tissues

  2018cites this paper